Evidence map›Paper›PMID 40589762›Full record

ReviewFrontiers in immunology2025

The reprogramming factor KLF4 in normal and malignant blood cells.

H Daniel Lacorazza

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

H Daniel LacorazzaDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, United States.

Funding

Targeting DYRK2 to eradicate leukemia stem cells in chronic myeloid leukemia.R01CA283079 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Daniel Lacorazza · 2024 to 2026
$1.2M
Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic LeukemiaR21CA286412 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LACORAZZA, DANIEL · 2024 to 2024
$413k
NCI NIH HHS R01 CA283079NCI NIH HHS R21 CA286412
6 · The paper itself

Abstract

The Krüppel-like factor 4 (KLF4) is an evolutionarily conserved zinc finger transcription factor that regulates cellular processes in stem cells, epithelial cells, and immune blood cells by controlling gene expression through genetic, epigenetic, and chromatin remodeling. The landmark 2006 publication identified KLF4 as one of the factors involved in reprogramming differentiated cells into pluripotent stem cells, sparking increased interest in KLF4 research a decade after its discovery, particularly in the fields of stem cell research, epithelial cell biology, endothelial cell function, and tumorigenesis. Over the years, KLF4 has emerged as a key transcription factor in modulating innate and adaptive immunity, especially in macrophage differentiation and function. This review summarizes the key findings regarding KLF4 in normal blood cells and leukemia.

Indexed as

Blood CellsCellular ReprogrammingKruppel-Like Transcription FactorsLeukemiaAnimalsCell DifferentiationHumansKruppel-Like Factor 4KLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription Factorshematopoietic stem cellsKLF4leukemiaT cellstranscription factor

Identifiers

PMID40589762
PMCPMC12206627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.